Abstract
Objective To observe the effect of eproxorubicin combined with iritecan on serum Th1 and Th2 cytokines in patients with cervical cancer. Methods From June, 2016 to December, 2018, 86 patients with cervical cancer treated at our hospital were randomly divided into two groups, 43 for each group. Extensive hysterectomy and pelvic lymph node dissection were performed in both groups. On this basis, the control group was treated with eproxorubicin, while the observation group with eproxorubicin and iritecan. The clinical efficacy, serum Th1 and Th2 cytokines, and Th1/Th2 were compared between the two groups. Results The total effective rate of the observation group was significantly higher than that of the control group (88.37% vs. 69.77%, P 0.05). After the treatment, IFN-γ/IL-4, IFN-γ/IL-6, IL-2/IL-4, and IL-2/IL-6 were in the observation group, which were lower than those in the control group (all P<0.05). Conclusion Eproxorubicin combined with iritecan for patients with cervical cancer can effectively reduce the levels of serum Th1 and Th2 cytokines and Th1/Th2 ratio, and the clinical effect is remarkable Key words: Cervical cancer; Epicorubicin; Iritecan; Th1 and Th2 cytokine levels
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
